Circulation 日本版

Associate Editor, Circulation

[Shinya Goto @sgoto4]

学術雑誌編集委員の大任をようやく終えました！｜sgoto3 https://t.co/SanTPx33UP

[Shinya Goto @sgoto4]

祖父が孫に誇る自慢： おじいちゃんは世界に冠たるCirculationのEditorをしていたんだよ！｜sgoto3 https://t.co/TOUiG67Fs6 祖父が孫に誇る自慢： おじいちゃんは世界に冠たるCirculationのEditorをしていたんだよ！

[Shinya Goto @sgoto4]

祖母が、ご先祖は福沢諭吉の弟子だと言っていたが本当だった！

[Circulation @CircAHA]

SREBP1 transactivates NHE3 in cardiomyocytes during HFpEF, leading to calcium mishandling and impaired contractility in heart failure.https://t.co/czFVb7JbKi

[Circulation @CircAHA]

Alternative splicing of Tropomyosin 1 (TPM1b) exon 9a is a pathogenic mechanism in myofilament disorder and diastolic dysfunction in HFpEF and is mediated by SRPK3. This may represent a novel therapeutic target for HFpEF.https://t.co/vSPCP57Xea

[Circulation @CircAHA]

Sam68, a stress-activated cardiomyocyte scaffold, drives pathological cardiac hypertrophy by scaffolding Src–STAT3 to induce PDK4 and suppressing cardiomyocyte glucose Oxidation https://t.co/rDrl7YESf2

[Shinya Goto @sgoto4]

慶應の高校に受かった時、祖母が、しんちゃんは経済に行って銀行に務めるといいと言った。祖母は、しんちゃんのひいおじいちゃんは福沢諭吉の門下生で慶應義塾の理財科に行っていたと言っていた。根拠を探していたら見つかった。日本は今の所記録がしっかりしているね

[Baim Institute @BaimInstitute]

Passing the Torch?: A Next-Generation High-Sensitivity Cardiac Troponin T Assay.

https://t.co/RC3tJzTLFT

Contributions from Baim CSO, James Januzzi and Baim faculty, @CianPMcCarthy.

#BaimInstitute #ClinicalResearch #Cardiology

[Circulation @CircAHA]

LVAD support enhances heart recovery by boosting capillaries, reducing fibrosis, and driving fibroblast-to-endothelial switching via c-Myc, revealing new regenerative pathways for HF therapy.🫀@hfdocbhimaraj @kaifu3 @na https://t.co/YaiyqEu5CU

[TIMI Study Group @TIMIStudyGroup]

In a large CICU validation cohort of predictive biomarkers, FGF-23, GDF-15, & sST2 discriminated cardiogenic shock from non-shock controls, while FGF-23 also distinguished cardiogenic from distributive shock & was independently assoc w/in-hospital mortality @NicholasChiuMD #ACC26

[TIMI Study Group @TIMIStudyGroup]

In a broad cohort of CICU patients, DPP3 was elevated in both shock and non-shock states and was associated with in-hospital mortality across the spectrum of CV critical illness. @Gurleen_Kaur96 #ACC26

[TIMI Study Group @TIMIStudyGroup]

See Annabel Wang present her work, "Apolipoprotein C-III (APOC3) Inhibition in Patients With VS Without Baseline Fibrate Use", in this analysis from CORE (TIMI 72a), CORE2 72b & ESSENCE CS9 – TIMI 73b, in 24 hrs on the Highlighted Original Research Stage @BrianBergmark #ACC26

[TIMI Study Group @TIMIStudyGroup]

Analysis of >71K pts from #COMBINE-AF shows pts with paroxysmal AF at lower risk for stroke/systemic embolism and death, but higher risk of bleeding and MI in an adjusted analysis compared to patients with persistent/permanent AF @rgiugliano
https://t.co/iJTYJgvUj5

[TIMI Study Group @TIMIStudyGroup]

The Centennial Manuscript – “SEEs in AFib: Data From COMBINE AF” by @sameralsaid et al., out now in @CircAHA, is the 100th paper published which includes data from the #ENGAGE AF-TIMI 48 trial, which concluded in 2013! @rgiugliano
https://t.co/SJl58cojfV

[NEJM @NEJM]

New Review Article: The Inherited Basis of Coronary Artery Disease 👉 https://t.co/eeAlH3mlEL

Coronary artery disease develops from an interplay of behavioral, environmental, genetic, and stochastic factors. Smoking, hypertension, hyperlipidemia, and diabetes mellitus are well-recognized modifiable risk factors for coronary artery disease, which affects almost 1 in 2 men and 1 in 3 women during their lifetime. More than a century ago, Osler posited that inherited factors may cause coronary artery disease after he observed that angina pectoris often clusters in families. Approximately 30 years ago, twin studies indicated that the heritability of fatal coronary artery disease was as high as 50%. Since 2007, large-scale genotyping and gene-sequencing studies have identified hundreds of genetic variants associated with increased susceptibility to coronary artery disease (seen in figure). Protein products of some associated genes already constitute effective treatment targets, and other genes point to currently unexplored disease mechanisms.

An inquiry about a family history of coronary artery disease is routine in the clinical assessment of patients presenting with chest pain syndromes. Heribert Schunkert, MD, Pradeep Natarajan, MD (@pnatarajanmd), and Nilesh J. Samani, MD, review recent discoveries regarding the molecular genetic origins of coronary atherosclerosis and discuss current and potential clinical uses of this information.

Read the Review Article “The Inherited Basis of Coronary Artery Disease” from Universitätsklinikum der Technischen Universität München; Deutsches Zentrum für Herz- und Kreislaufforschung, Partner Site Munich Heart Alliance (@dzhk_germany); and elsewhere: https://t.co/eeAlH3mlEL

[Circulation @CircAHA]

Explore the most-cited research of 2025 from the American Heart Association Journals shaping cardiovascular science—from global trends and stroke prevention to AI-driven precision medicine and innovative therapies. Access these influential articles now. https://t.co/svOCFoEiDr

[Shinya Goto @sgoto4]

脱炭素社会の実現へ　第２回「かながわ脱炭素大賞」表彰式 https://t.co/AZiLXyskTq @YouTubeより My ground daughter was awarded!

[ISTH @isth]

The Guidelines and Guidance Committee is pleased to announce that the guidance manuscript “The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH” is now open for public comment: https://t.co/hx2eVk0633

[ISTH @isth]

Extra! Extra! Read all about the ISTH 2026 Congress Chronicle: February edition. Registration is officially open, hotels are now available, and excitement is building for #ISTH2026

Read more: https://t.co/YySQVM4ZUW

[Shinya Goto @sgoto4]

Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction | New England Journal of Medicine https://t.co/GPRy7FrDi4 EFが落ちていないと心筋梗塞後のベータ遮断薬の効果は明確ではないね。